GlassScriptPhysician profile
Nidhi N Patel
NPI 1316576010
$1,341.19
in general payments reported to CMS, 2019-2025
17 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $163 · 2024: $663 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.69 | 2023-2025 | |
| Novo Nordisk INC | $239.72 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $119.46 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.05 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $102.38 | 2023-2025 | Veozah |
| Lilly USA, LLC | $101.20 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $60.22 | 2023-2024 | |
| Glaxosmithkline, LLC. | $54.82 | 2023-2025 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $48.00 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $30.71 | 2024-2025 | Farxiga |
| Dynavax Technologies Corporation | $30.23 | 2025 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $27.59 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $27.56 | 2025 | Inspire |
| Shield Therapeutics INC | $19.98 | 2025 | |
| Biotronik Nro, INC. | $19.32 | 2025 | Prospera |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $18.33 | 2025 | Neffy |
| Pulmonx Corporation | $13.93 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidhi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.